探讨rhTPO与rhIL-11在急性髓系白血病化疗后血小板减少中的疗效
|
摘要
目的探讨重组人血小板生成素(rhTPO)与重组人白细胞介素-11(rhIL-11)在急性髓系白血病化疗后血小板减少中的疗效。方法选取本院血液内科收治的急性髓系白血病患者24例,随机平均分成两组,均给予标准的DA(3+7)方案化疗,化疗后观察组给予rhTPO促进血小板生成,对照组给予rhIL-11促进血小板生成,观察两组患者化疗后骨髓抑制的血小板恢复时间。结果观察组患者血小板恢复时间较对照组明显缩短,两组差异有统计学意义(P<0.05),两组患者的不良反应发生率无明显差异(P=0.590)。结论使用rhTPO的患者血小板恢复时间较rhIL-11明显缩短,不良反应较轻,但由于rhTPO价格昂贵,应根据患者经济条件等情况综合考虑而使用。
Objective To explore the therapeutic effect of rhTPO( recombinant human thrombopoietin)and rhIL-11( recombinant human interleukin-11) in the treatment of thrombocytopenia caused by chemotherapy of AML.Methods 24 patients with acute myeloid leukemia were selected from Hematology Department of our hospital,and randomly divided into 2 groups,all treatment by the therapeutic regimen of DA( 3 + 7); The observation group received by rhTPO treatment and the control group received by rhIL-11 treatment; observed the convalescence of thrombocyte between the two groups. Results Patients in the observation group were significantly shorter than those in the control group,the difference between the two groups was statistically significant( P<0.05),there was no significant difference in the incidence of adverse reactions between the two groups( P = 0. 590). Conclusions The recovery time of platelet in patients with rhTPO is significantly shorter than that in rhIL-11 group,and the adverse reaction is lighter,however,due to the high cost of rhTPO,the use should be based on the patient's economic conditions,etc.
Objective To explore the therapeutic effect of rhTPO( recombinant human thrombopoietin)and rhIL-11( recombinant human interleukin-11) in the treatment of thrombocytopenia caused by chemotherapy of AML.Methods 24 patients with acute myeloid leukemia were selected from Hematology Department of our hospital,and randomly divided into 2 groups,all treatment by the therapeutic regimen of DA( 3 + 7); The observation group received by rhTPO treatment and the control group received by rhIL-11 treatment; observed the convalescence of thrombocyte between the two groups. Results Patients in the observation group were significantly shorter than those in the control group,the difference between the two groups was statistically significant( P<0.05),there was no significant difference in the incidence of adverse reactions between the two groups( P = 0. 590). Conclusions The recovery time of platelet in patients with rhTPO is significantly shorter than that in rhIL-11 group,and the adverse reaction is lighter,however,due to the high cost of rhTPO,the use should be based on the patient's economic conditions,etc.
引文
[1]张之楠,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:214-215.
[2]P eterson DE.Pretreatment startegiea for infection prevetion in chemotherapy patients[J].NCI Monogr,1990,9:61-71.
[3]凌桂琴,陈东波,王宝庆.重组人血小板生成素治疗肿瘤化疗后血小板减少的临床观察[J].吉林医学,2014,35(19):4228-4230.
[4]赵永强,姜杰玲,焦力,等.重组人血小板生成素临床耐受试验[J].重庆医学,2010,39(7):878-881.
[5]付岭,张涛,刘金梅,等.重组人血小板生成素与白介素-11治疗白血病化疗后血小板减少症的疗效比较[J].临床军医杂志,2014,42(3):240-242.
[2]P eterson DE.Pretreatment startegiea for infection prevetion in chemotherapy patients[J].NCI Monogr,1990,9:61-71.
[3]凌桂琴,陈东波,王宝庆.重组人血小板生成素治疗肿瘤化疗后血小板减少的临床观察[J].吉林医学,2014,35(19):4228-4230.
[4]赵永强,姜杰玲,焦力,等.重组人血小板生成素临床耐受试验[J].重庆医学,2010,39(7):878-881.
[5]付岭,张涛,刘金梅,等.重组人血小板生成素与白介素-11治疗白血病化疗后血小板减少症的疗效比较[J].临床军医杂志,2014,42(3):240-242.